London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)

Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as a potential maintenance therapy for acute myeloid leukaemia (AML), with the latest update presented at the 66th annual American Society of Hematology (ASH) meeting in December. Mendus presented encouraging long-term survival data from the ADVANCE II trial investigating vididencel as monotherapy, which we believe bolsters the case for further development as it advances towards pivotal studies. With a net cash position of SEK108.5m at Q324, Mendus is funded through 2025, past key milestones for the AML programme. We value Mendus at SEK40.3/share, versus SEK39.8/share previously.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234116